Overview

Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis

Status:
Not yet recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
This study is a single-center, randomized, double-blind, placebo parallel-controlled, dose-escalation clinical study. The aim of this study was to evaluate the safety, tolerability, and preliminary effect of Aleeto in adult patients with ALS, and to provide an appropriate dose for the future clinical trial.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Tiantan Hospital